Biopharma Compass: Next Generation Therapeutic Protein Characterization By Mass Spectrometry

Featured Product   May 29, 2018

 
Biopharma Compass: Next Generation Therapeutic Protein Characterization By Mass Spectrometry
 
 
 
Company Details:
Bruker Daltonics
Fahrenheitsstraße 4,
28359 Bremen,
Germany
Tel: +49 42122050
Email: Guillaume.Tremintin@Bruker.com
 
 
 

Other Products From This Vendor

mAb development made easy with maXis II ETD
mAb development made easy with maXis II ETD
Product

Fast characterization methods are essential to efficiently support the development of therapeutic proteins. The maXis II ultrahigh resolution QTOF helps BioPharma scientists with delivering timely answers to the development teams. The ability to measure the True Isotopic Pattern of light and heavy chain of a monoclonal antibody allows for high mass accuracy measurement with high dynamic range. This is why maXis II is the class leading instrument for any fast screening experiments, such as determination of a protein glycan profile. In addition, the native MS capability makes the maXis II an excellent platform for the precise determination of drug distribution and drug to antibody ratio which are important attributes in the development of ADCs. Finally the combination of CID and ETD with ultrahigh resolution permits the top-down sequencing of proteins at the HPLC timescale which provides maXis II users with a powerful toolbox to investigate unexpected impurities.

LEARN MORE

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy